Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development. Short NJ, Dillon R. Am J Hematol 2025;100 Suppl 2:5-15.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Short NJ, Dillon R. Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development. Am J Hematol 2025;100 Suppl 2:5-15.
PMID: 39319951